SAN DIEGO, Oct. 22 TargeGen, Inc. today announced that the Company has successfully completed a 59 patient, multicenter clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis.
There are no currently approved specific therapies for myelofibrosis (MF), polycythemia vera (PV), or essential thrombocythemia (ET), which collectively constitute the major myloproliferative diseases. These disorders are estimated to affect more than 200,000 patients in the United States and over twice that total worldwide.
The current clinical trial was conducted at six centers in the USA. The trial was divided into two phases: a dose-escalation phase that enrolled 28 patients, followed by a dose-confirmation phase that enrolled 31 patients. The primary goals of this open-label, dose-escalation study included identification of a maximum tolerated dose (MTD), characterization of the safety profile, and evaluation of drug effects of TG101348 on surrogate markers, biomarkers, and presumptive clinical endpoints.
The results of this study have been accepted for oral presentation at the American Society of Hematology (ASH) Annual Meeting in New Orleans, December 5-8, 2009.
About TargeGen, Inc.
TargeGen, Inc. is a privately held biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors for the treatment of hematological malignancies and certain other disorders.
SOURCE TargeGen, Inc.